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Entry of the bacterial pathogenListeriamonocytogenes into host
epithelial cells is critical for infection and virulence. One major
pathway forListeria entry involves binding of the bacterial protein
Internalin B to the host receptor tyrosine kinase Met (hepatocyte
growth factor receptor).ActivationofMet anddownstreamsignal-
ing cascades is critical for Listeria entry. Internalin B is composed
of several structural domains including anN-terminal leucine-rich
repeat that is sufficient for binding Met and stimulating down-
stream signal transduction. Internalin B is monomeric, whereas
the leucine-rich repeat is dimeric when expressed as an isolated
fragment. The different quaternary states of Internalin B and the
leucine-rich repeat suggest that these twoMet ligandsmight cause
distinct biological effects. Here we demonstrate that Internalin B
and the leucine-rich repeat fragment exhibit agonist properties
that differentially influence Met down-regulation in lysosomes.
Specifically, Met stability is increased in response to the leucine-
rich repeat fragment compared with Internalin B. Interestingly,
Internalin B and the leucine-rich repeat stimulate equivalent rates
of clathrin-mediated Met internalization. However, the leucine-
rich repeat is defective inpromoting lysosomal down-regulationof
Met and instead enhances receptor recycling to the cell surface. In
addition, the leucine-rich repeat causes prolonged Met activation
(phosphorylation)andincreasedcellmotilitycomparedwithInterna-
linB.Takentogether,our findings indicate that individualdomainsof
Internalin B differentially regulate Met trafficking. The ability of the
leucine-richrepeat fragment topromoteMetrecyclingcouldaccount
for the increased cellmotility inducedby this ligand.
The Listeria monocytogenes surface protein Internalin B
(InlB)2 is a 630-amino acid protein critical for bacterial invasion
into a broad range of host cells including endothelial cells,
hepatocytes, and epithelial cell lines such as Vero and HeLa
cells (1–4). In addition to the bacterial-bound form, soluble
InlB is detected in bacterial supernatants (5, 6) and is active in
promoting Vero cell infection by a Listeriamutant lacking InlB
(7). The host receptor for InlB isMet, a receptor tyrosine kinase
for the endogenous ligand hepatocyte growth factor (HGF)
(8). Tight regulation of Met signaling elicits multiple cellular
responses critical for mammalian development including
proper cellular growth, survival, and migration (for review, see
Ref. 9). In adult tissues, Met signaling is intrinsic for organ
homeostasis and tissue remodeling (10–12).
InlB shares many of the agonist activities of HGF including
increased cell proliferation, epithelial cell motility, and mem-
brane ruffling (5, 8, 13). Recent structural studies show that
HGF and InlB directly bind to discrete sites on the extracellular,
sema domain of Met (14–16), consistent with early biochemi-
cal studies showing that InlB and HGF do not compete for
receptor occupancy (8, 14). Despite these differences, HGF and
InlB activate similar signaling cascades downstream of Met
autophosphorylation including pathways involving Grb2,
Gab1, phosphatidylinositol 3-kinase and MAP kinase (MAPK)
(2, 5, 7, 17, 18). We previously reported that like HGF, InlB
induces Met endocytosis in a process requiring clathrin-heavy
chain, the clathrin adaptor epidermal growth factor phospho-
rylation substrate 15 (Eps15), Grb2, and the E3 ubiquitin ligase
Cbl (18, 19). After internalization, InlB- and HGF-activated
Met are targeted for lysosomal degradation.Met degradation is
dependent on phosphatidylinositol 3-kinase activity and hepa-
tocyte receptor substrate (Hrs) (18), a protein that interacts
with ubiquitinated cargo and is important for endosomal sort-
ing (20–23).
InlB is a modular protein consisting of a N-terminal cap fol-
lowed by a 213-amino acid leucine-rich repeat (LRR), an inter-
repeat domain, and aC-terminal region containing “GW”mod-
ules that anchor InlB non-covalently to the bacterial cell wall
(24, 25). InlB binds Met in a 1:1 stoichiometry primarily
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through the concave surface of the LRR region, although a sec-
ond contact involving the inter-repeat region of InlB strength-
ens this interaction (14). Biochemical studies confirm that a
fragment containing only the N-cap and LRR domains (i.e. the
LRR fragment) comprises the minimal region for binding and
inducing Met phosphorylation (7, 8).
Surprisingly, the LRR fragment used in studies on Met acti-
vation (7, 17) has a different quaternary structure than InlB.
Whereas full-length InlB is monomeric, the isolated LRR
domain is a disulfide-linked dimer. LRR dimerization results
from a cysteine residue in InlB that is normally unavailable for
disulfide formation. Truncation of InlB to generate the LRR
fragment results in the surface exposure of this cysteine residue
located near the C terminus of the LRR fragment. The different
quaternary structures of monomeric InlB and the dimeric LRR
fragment raise the possibility that these two Met ligands could
exhibit some differences in biological activity.
Although it is unclear whether the LRR fragment is produced
physiologically during Listeria infection, we are interested in
using InlB and its derivatives as tools to examine aspects of
Met-mediated signal transduction and trafficking. Our struc-
ture/function analysis of InlB identified the LRR fragment with
agonist properties reminiscent of InlB, with the exception that
LRR promotes Met stability. Down-regulation plays a key role
in regulating the temporal activity of signaling receptors, and
mutations or other conditions that interfere with down-regu-
lation are thought to contribute to the development of several
cancers (26, 27). “Down-regulation” refers to ligand-induced
depletion of a surface receptor, typically resulting from recep-
tor internalization and degradation in a lysosomal compart-
ment (28). We found that compared with InlB, the LRR frag-
ment is defective in promoting Met down-regulation. LRR and
InlB induce Met internalization at similar rates, indicating that
the differences in receptor degradation caused by these two
ligands are due to alterations in intracellular trafficking. Com-
pared with InlB, the LRR fragment is defective in targetingMet
to the degradative pathway and, instead, promotes receptor
recycling to the plasmamembrane. InlB and LRR are compara-
ble in their abilities to induce initial Met activation (i.e. Met
tyrosine phosphorylation); however, receptor phosphorylation
in response to the LRR fragment is more sustained than that
induced by InlB. The ability of LRR to prolong Met phospho-
rylation raised the possibility that the truncated ligandmight be
more potent than InlB for inducing one or moreMet-mediated
biological activities. Consistent with this idea, we show that the
LRR fragment was more effective than InlB in promoting epi-
thelial cell motility. Collectively, our results indicate that indi-
vidual domains of InlB differentially regulate Met trafficking
and impact Met-mediated biological activity.
EXPERIMENTAL PROCEDURES
Reagents, Antibodies, and Plasmids—All general reagents
were obtained from Fisher or Sigma-Aldrich unless indicated
otherwise. The following antibodies were purchased as indi-
cated: transferrin receptor (Invitrogen), anti-actin (Sigma-Al-
drich), anti-human HGF receptor (R & D Systems Inc., Minne-
apolis, MN), clathrin heavy chain (CHC), caveolin, EEA1 (BD
Biosciences), Met C-12, andMet C-28 (Santa Cruz Biotechnol-
ogies Inc, Santa Cruz, CA), phospho-Met Tyr-1234, Tyr-1235
(Upstate Biotechnology, Billerica, MA), phospho-Met Tyr-
1003 (ABR-Affinity BioReagents, Golden, CO), peroxidase-
conjugated goat anti-mouse immunoglobulinG (IgG), and goat
anti-rabbit IgG (Jackson ImmunoResearch Laboratories, Inc.,
West Grove, PA). Plasmids encoding N-terminal His-tagged
LRR or LRR-C242A construct in pET28a were kindly provided
by Dr. Partho Ghosh (University of California, San Diego, CA)
and have been described elsewhere (17, 18, 25). Recombinant
human HGF was purchased from PeproTech Inc, Rocky Hill,
NJ, and Alexa594-labeled-transferrin (Tfn) and Alexa594-la-
beled dextran was obtained from Invitrogen.
Cell Line and Cell Culture—Human cervical epithelial ade-
nocarcinoma (HeLa) andMadin-Darby canine kidney (MDCK)
cells were grown in complete media (Dulbecco’s modified
Eagle’smedium supplementedwith 10% fetal bovine serum and
1penicillin/streptomycin) at 37 °Cwith 5%CO2.TheH10 cell
line derived from kidney epithelial cells from embryos of Met
null / mice (29) was kindly provided by Dr. Lloyd Cantley
(Yale University School of Medicine). H10 derivatives stably
expressing wild type (WT) or mutant Met alleles (KinD) (19)
were grown in the Dulbecco’s modified Eagle’s medium/F-12
(1:1)media supplementedwith 10% fetal bovine serum, 5g/ml
puromycin at 37 °C with 5% CO2. Cells were routinely starved
in media lacking sera (incomplete media) overnight at 37 °C
before use unless specified otherwise. For studies using
cycloheximide, cells were pretreated with 10 g/ml cyclo-
heximide at 37 °C for 30–60 min to prevent de novo synthe-
sis of Met during receptor stimulation as indicated in the
appropriate figure legends.
Ligand Purification and Labeling, Confocal Microscopy—
The purification and labeling of InlB and its derivatives has
been described in detail elsewhere (18). Gel filtration chroma-
tography was used to separate dimeric LRR from LRR mono-
mers. Briefly, 2–2.5 mg of LRR in 120 l was injected (10
l/run) onto a Superdex 75 (GE Healthcare) gel filtration col-
umn at a flow rate of 1 ml/min in 500 mMNaCl, 50 mMHEPES,
pH 7.4, and the separation of LRR dimers frommonomers was
monitored by size and SDS/PAGE. For confocal microscopy,
serum-starved cells grown on coverslips were co incubated in
incomplete media containing 5.0 g/ml Alexa594-labeled Tfn
or 5.0 g/ml Alexa594-labeled dextran with 2 nM Alexa488-la-
beled InlB or 2 or 10 nM Alexa488-labeled LRR or LRR-C242A.
The cells were rapidly cooled and analyzed for ligand uptake as
previously published (18, 19). All images were taken using iden-
tical acquisition parameters, and the amount of internalized
LRR or LRR-C242A is expressed as a percentage of internalized
InlB. Colocalization analyses were preformed as previously
described (30) on cells stained for endogenous EEA1 or CD63.
Routinely, aminimumof 10 cell areaswas analyzed usingMeta-
Morph software v7.1.3.0 (Molecular Devices, Union City, CA),
and the data were normalized to the percentage of co-localiza-
tion with EEA1 at the 0-min chase time.
Flow Cytometry-based Recycling Assay—Serum-starved
HeLa cells grown on 10-cm plates were incubated with 10
g/ml cycloheximide for 1 h at 37 °C to inhibit protein synthe-
sis. The cells were then stimulated with 2 nM InlB or 10 nM LRR
for 15 min at 37 °C to induceMet internalization. Residual sur-
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faceMet was cleaved by incubationwith 0.25% trypsin (Invitro-
gen) for 30 min on ice. Cells were collected by centrifugation
and washed in PBS containing 2% fetal bovine serum (FACS
buffer) before resuspension in serum-free media containing 10
g/ml cycloheximide. Cells were incubated at 37 °C for 0, 5, 10,
or 15 min to allow Met trafficking. After the appropriate chase
time cells were shifted to ice to prevent further endocytic traf-
ficking of Met and were resuspended to a concentration of 1
107 cells/ml in FACSbuffer. To determine the level ofMet pres-
ent on the cell surface, 2 105 cells were aliquoted into tripli-
catewells of a 96-well plate. Cells were incubatedwith 10g/ml
goat anti-HGF receptor antibody for 30 min on ice followed by
20 min of incubation with donkey anti-goat phycoerythrin-
conjugated secondary antibody. After staining, cells were fixed
with 2% formaldehyde (Ted Pella Inc., Redding, CA) in FACS
buffer for 20 min at room temperature. Residual formaldehyde
was removed by washing in FACS buffer before measurement
of the mean yellow fluorescent signal for 20,000 events by a BD
FACSArray. Experiments were performed in triplicate, and the
values were expressed as the level of Met present on the cell
surface after each chase time. Data were normalized to the level
of Met present on the cell surface after 0 min of chase, so that
the surface level of Met at time 0 was 1.
Small Interfering RNA (siRNA) Transfection Studies—siRNA
depletion experiments were performed using commercially
available control, Grb2, and Met (Dharmacon, Chicago, IL)
or CHC (Santa Cruz Biotechnologies Inc., Santa Cruz, CA)
siRNAs. Cells were cultured for 1 day before transfection and
transfected using empirically determined concentrations of
siRNA using Lipofectamine 2000 reagent (Invitrogen) accord-
ing to the manufacturer’s specifications. Typically cells were
treated with 40–60 pmol of siRNA with 1–1.5 l of Lipo-
fectamine 2000, respectively, to routinely accomplish a 95%
decrease in protein levels as determined by Western analysis.
All experiments were routinely performed 72 h after siRNA
transfection.
Cell Surface Enzyme-linked Immunosorbent Assay—Dupli-
cate sets of HeLa cells were plated in 4-well tissue culture plates
(Nunc A/S, Rochester, NY) at a concentration of 2 105/well.
The following day sera-starved cells were stimulated with 2 nM
InlB, 2 nM LRR, 10 nM LRR, or 2 nM LRR-C242A in incomplete
media for 2–8min at 37 °C. The cells were rapidly cooled on ice
to inhibit endocytosis, washed three times with ice-cold PBS,
and then fixed with 4% formaldehyde (Ted Pella Inc., Redding,
CA) in PBS for 10 min at room temperature. The cells were
incubated with primary anti-human HGF receptor antibody in
PBS containing 10% horse serum for 1 h at room temperature,
and unbound antibody was removed using three ice-cold PBS
washes, then incubated with the appropriate horseradish per-
oxidase-conjugated secondary antibody. For measuring total
receptor, one duplicate plate of cells was first fixed in paraform-
aldehyde and then permeabilized with 0.2% Triton X-100 for 5
min before the addition of the primary antibody. One well of
cells lacking primary antibody was used as an additional nega-
tive control. Todetect antibody-boundprotein complexes, cells
were incubated with 1-Step-ABTS reagent (Thermo Scientific,
Rockford, IL) for 30 min at room temperature, and the colori-
metric reaction was terminated by the addition of 1% SDS. The
absorbance at 405 nmwasmeasured using aVERSAmaxmicro-
plate reader and SOFTmax PRO 3.0 software (Molecular
Devices, Sunnyvale, CA). Experiments were performed in trip-
licate, and values were calculated as the ratio of surfaceMet (X)
to total receptor (Y) at each time point (tx), normalized to the
control value at time zero (t0). For the kinetic studies, values
representing the relative amount of internalized Met were cal-
culated using the formula ((X/Y)t0 (X/Y)tx)/tx.
Western Blot Analysis—Western analysis was performed
using ECL plus (GE Healthcare), and the resulting digitized
blots were quantified using MetaMorph software as previously
described (19).
Wound Healing and Three-dimensional Tubulogenesis
Assays—Cell migration was analyzed using an in vitro wound-
healing model (31). Briefly, confluent monolayers of MDCK or
HeLa cells were cultured in 6-well plates and serum-starved for
48 or 24 h, respectively, in media supplemented with 0.2% fetal
bovine serum before each experiment. MDCK cells were
wounded mechanically by scraping with a 200-l pipette tip (3
separate wounds per well). Immediately after wounding, the
cells were incubated in media containing ligand. At the indi-
cated time points after wounding, wound areas were imaged
with a NIKON TE2000 multifunction inverted microscope.
Multiple positioning marks were made to ensure that identical
areas were imaged between time points. The relative gap dis-
tance from three independent experiments was measured in
pixels usingMetaMorph software.MDCK tubulogenesis assays
were performed in three-dimensional matrix gels as previously
described (32). Briefly, MDCK cells were trypsinized and sus-
pended at 3 104 cells/ml in a neutralized rat tail collagen type
I (BD Biosciences) solution composed of 3.5 mg/ml glutamine,
2.35 mg/ml NaHCO3, 1 minimum Eagle’s medium, 20 mM
Hepes (pH 7.6), and 2 mg/ml collagen I. 150 l of the cell-
collagen I mixture was added to each well of 8-well culture
slides. After the collagen gel solidified, the cells were incubated
in complete media, which was changed every other day. Cysts
routinely formed at 7–8 days under these conditions. For
inducing tubulogenesis, cysts were incubated in complete
media containing 2 nM InlB, 2 nM HGF, or 10 nM LRR and
renewed every 24 h. One group of cells incubated in growth
media lacking ligand served as a control. Phase contrast imag-
ing was preformed using a NIKON TE2000 multifunction
inverted microscope equipped with a 20 objective.
RESULTS
TheLRRFragment IsUnable toTargetMet to theDegradative
Pathway—We previously reported using InlB as a tool to
understand the molecular mechanisms of Met endocytosis and
intracellular trafficking (18, 19). In particular, we were inter-
ested in identifying theminimal region of InlB required forMet
internalization and degradation. We focused on the LRR frag-
ment of InlB (herein referred to as LRR) as it has been shown to
bind Met, induce receptor tyrosine phosphorylation, and acti-
vate downstream signaling cascades (7, 8, 33). InlB and LRR
were expressed and purified as recombinant His-tagged pro-
teins and used to examine Met endocytosis and degradation.
Non-reducing SDS-PAGE shows that, consistent with earlier
reports (7, 8), InlB purifies as a monomeric species, whereas
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LRR is composed of monomers and disulfide-linked dimers
when purified under non-reducing conditions (supplemental
Fig S1A). LRRdimers convert to inactivemonomers in the pres-
ence of reducing agents. Conversely, an LRR mutant incapable
of forming disulfide-linked homodimers due to a mutation in
the sole cysteine residue in LRR (C242A) purifies as a mono-
meric species under non-reducing conditions (supplemental
Fig S1A). To confirm that LRR dimers but not LRR monomers
are functionally active, the LRR preparation was subjected to
sizing chromatography. Fractions enriched in LRR monomers
or dimers were isolated, and their ability to induce Met phos-
phorylation at tyrosine 1234 and 1235 in theMet kinase domain
was examined. For these studies we used HeLa cells, an estab-
lished cell model for examining the mechanisms for receptor
endocytosis and degradation. HeLa cells express high levels of
Met on their surface and have a well documented response to
Met signaling (34–36). Western analysis using site-specific
phosphotyrosine antibodies confirmed tyrosine phosphoryla-
tion at positions 1234 and 1235 in response to dimeric LRR
(supplemental Fig. S1, B and C). Met activation was not
detected in response to monomeric LRR or the mutant LRR-
C242A, consistent with a previous study (7).
We next examined the fate of internalizedMet in response to
InlB or LRR treatment. Two different LRR concentrations (2 or
10 nM) were used, as discrepancies in the level ofMet activation
by LRR have been reported (7, 8, 14) possibly due to differences
in ligand preparations. HeLa cells pretreated with 10 g/ml
cycloheximide (30min) were incubated inmedia lacking ligand
or with LRR or InlB for 10, 30, 60, or 120 min in the continued
presence of cycloheximide (Fig. 1,A andB). Cycloheximidewas
included to prevent newprotein synthesis that would otherwise
contribute to an underestimation ofMet degradation. The level
ofMet and activated receptor (as assessed by tyrosine phospho-
rylation of residues 1234 and 1235) decreased in response to
InlB over the time course of the experiment (Fig. 1B). Quanti-
fication of the Western bands revealed that levels of Met and
phospho-Met 60–120 min after treatment with InlB were neg-
ligible, consistent with ligand-induced receptor internalization
and degradation. The apparent increase in Met levels at 5 min
was not observed in repeats of the experiment and is not statis-
tically significant. Interestingly, treatment with 10 nM LRR, and
to a lesser extent, 2 nM LRR caused a delay in Met degradation.
Whereas total Met was reduced to 32.6% that of its original
levels in cells treated with InlB at 60 min, the steady state levels
of Met in response to 2 nM LRR and 10 nM LRR only decreased
to 64.8 and 86.8% that of starting levels, respectively (Fig. 1C).
These results indicate that LRR is less effective than InlB in
promoting Met degradation. In addition, Met phosphorylation
at tyrosine 1234 and 1235 was sustained up to 120 min in cells
treatedwith LRR,whereas phospho-Metwas undetectable after
30 min in response to full-length InlB (Fig. 1). Hence, the
decrease in Met degradation observed in response to LRR cor-
relates with prolonged Met activation.
The LRR Fragment and InlB Induce Comparable Met
Activation—We previously reported that Met kinase activity
was required for receptor endocytosis and, hence, degradation
in response to InlB (19). The differences we observed in LRR-
versus InlB-induced Met degradation could be the result of
compromised Met activation. Therefore, we examined Met
phosphorylation (i.e. activation) over a range of ligand concen-
trations. Western analysis of lysates prepared from HeLa cells
treated with 2 nM InlB using site-specific phosphotyrosine anti-
bodies detected Met phosphorylation at tyrosine 1003, 1234,
and 1235 (Fig. 2, A and B). Conversely, a comparable level of
Met phosphorylation in response to the LRR fragment was
only observed in cells treated with higher concentrations (10
nM) of this ligand (Fig. 2, A and B). As expected, no Met
activation was detected in control cells stimulated with LRR-
C242A. Contrary to our results, a previous study reported a
500-fold difference in the potency of the LRR fragment for
activating Met (7). The explanation for this discrepancy
remains unclear but may reflect differences in ligand prepa-
rations and/or cells lines used in the respective studies.
Regardless, our results and those reported by Banerjee et al.
(7) indicate that, when used at comparable concentrations,
the LRR fragment is a less potent Met agonist than full-
length InlB.
LRR Induces Normal Met Internalization—InlB induces Met
endocytosis through clathrin-coated pits in a Grb2-dependent
manner (18, 19). The delay in Met degradation observed in
response to LRR could be the result of altered kinetics for Met
FIGURE 1.Met degradation is delayed in response to LRR. A, structures of
full-length InlB and its N-terminal LRR fragment and themutant C242A.Num-
bers represent amino acids. B, HeLa cells were incubated in medium contain-
ing 10 g/ml of cycloheximide (37 °C/30 min) before stimulation with cyclo-
heximide-containing media supplemented with 2 nM InlB, 2 nM LRR, 10 nM
LRR, or medium lacking ligand (0 min) for the indicated times. The resulting
cell lysates were examined by Western analysis for total Met (Met), phospho-
rylatedMet (p-Met, Y1234, Y1235), and actin. C, meanMet protein levels S.E.
were quantified using MetaMorph software, and Met band density was nor-
malized to actin density in the corresponding lane. Representative data are
shown for 2–3 separate experiments.
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internalization and/or receptor endocytosis via a clathrin-inde-
pendent route. The rate of Met internalization in response to
InlB and/or LRR was examined using a cell surface enzyme-
linked immunosorbent assay to quantify the loss of surfaceMet
(Fig. 3). Duplicate sets of HeLa cells were treated with media
containing InlB or LRR for increasing times at 37 °C. The cells
were then rapidly cooled, and the relative amount of immuno-
reactive receptor remaining on the cell surface of one set of
plates was measured using an antibody specific to the extracel-
lular domain of Met. The second set of time-matched plates
was permeabilized and then incubated with anti-Met antibody
to measure the amount of total (cell surface plus intracellular)
receptor. The ratio of surface to total Met was plotted against
time as an indication of the relative amount of endocytosed
Met, and the specific internalization rate constant (Ke) for each
ligand was calculated as a linear regression coefficient (18). To
correlate the level ofMet phosphorylation with the internaliza-
tion rate, we used two different concentrations of LRR in these
studies, 2 and 10 nM LRR. As shown in Fig. 3A, treatment with 2
nM InlB caused rapidMet uptake from the cell surface (K InlBe 
0.102 0.007/min), consistent with our previous studies using
T47D/Met cells (18). A similar rate of receptorMet endocytosis
was observed inHeLa cells treated with 10 nM LRR (KLRRe (10 nM)
0.112  0.004/min), conditions that induce comparable levels
of Met phosphorylation as 2 nM InlB. However, Met internal-
ization was slower in response to 2 nM LRR (KLRRe (2 nm) 
0.061  0.004/min), which induced lower levels of receptor
phosphorylation than the same concentration of full-length
FIGURE 2.Met activation in response to the LRR fragment of InlB is dose-
dependent.A, HeLa cellswere treatedwithmediumcontaining InlB, LRR, the
mutant LRR-C242A, or lacking ligand (Con) as indicated for 5min at 37 °C. The
resulting cell lysates were examined byWestern analysis using antibodies for
total Met (Met), key phosphotyrosines in the cytosolic region of Met (Y1234,
Y1235, or Y1003), or actin. B, mean Met protein levels S.E. were quantified
using MetaMorph software, and Met band density was normalized to actin
density in the corresponding lane. Representative data are shown for 2–3
separate experiments.
FIGURE 3. LRR induces rapid internalization of Met. A, HeLa cells were
treated for 2, 4, and 8min inmediumwith InlB, LRR, or without ligand (0min)
at 37 °C. The cells were rapidly cooled to 4 °C, and the level of residual surface
Met was determined using a cell enzyme-linked immunosorbent assay for
Met. The ratio of surface to totalMetwas plotted against time as an indication
of the relative amount of internalized Met (see “Experimental Procedures”),
and the specific internalization rate constant (Ke) for each ligand was calcu-
lated as a linear regression coefficient S.E. Data are representative of three
independent experiments. B, HeLa cells were incubated in media containing
Alexa488-labeled InlB, LRR, or LRR-C242A at 37 °C for 10 min and analyzed by
confocalmicroscopy. Representative images of endocytosed InlB, LRR (closed
arrows), and low levels of LRR-C242A (open arrows) are shown. Scale, 10 m.
C, the relative amount of endocytosed ligand was quantified using Meta-
morph, and the data are normalized with respect to internalized InlB  S.E.
from 2–3 experiments (*, p 0.01 ANOVA).
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InlB. We confirmed our findings using confocal microscopy
(Fig. 3, B and C) with Alexa488-labeled LRR and Alexa488-la-
beled InlB to quantifyMet internalization. Serum-starvedHeLa
cells were incubated with Alexa488-labeled InlB (2 nM),
Alexa488-labeled LRR (2 nM or 10 nM), or Alexa488-labeled
mutant LRR-C242A (2 nM) for 10 min at 37 °C. Under these
conditions comparable levels of internalized ligand were
detected in HeLa cells treated with 10 nMAlexa488-labeled LRR
or 2 nM Alexa488-labeled InlB, whereas decreased ligand levels
were detected in cells treated with 2 nM Alexa488-labeled LRR.
As expected, negligible internalized ligand was detected in cells
treated with Alexa488-labeled LRR-C242A. Thus, InlB and LRR
are equally effective at triggering Met endocytosis under con-
ditions that induce comparable Met phosphorylation. Using
established populations of cell lines immortalized from the kid-
neys of Met null (/) mice that stably express comparable
levels of wild-type Met (WT-Met) or the kinase-deficient
mutant K1110A (KinD-Met), we confirmed that Met kinase
activity is required for receptor uptake in response to LRR. The
cells were incubated in media containing InlB or LRR at 37 °C
for increasing times, and the relative amount of internalized
WT-Met versus KinD-Met was examined using the surface
enzyme-linked immunosorbent
assay (supplemental Fig. S2). As
expected, treatment with InlB and
LRR causes WT-Met endocytosis.
Conversely, higher cell surface lev-
els of KinD-Met were detected at
each time point, indicating the need
forMet kinase activity in LRR-stim-
ulated receptor endocytosis, con-
sistent with our earlier studies using
InlB (19).
InlB and LRR Induce Clathrin-
mediated Met Endocytosis—We
used RNA interference to examine
whether Met internalization in
response to LRR is clathrin-medi-
ated and Grb2-dependent. HeLa
cells were transfected with siRNAs
targeting CHC or Grb2 (Fig. 4).
Under these conditions, near com-
plete depletion of CHC was achi-
eved. As expected, levels of Met,
transferrin receptor, and EEA1,
markers for clathrin-mediated en-
docytosis and early endosomes,
respectively (37–39), and caveolin 1,
a component of caveolae that has
been implicated in cell motility,
lipid trafficking and epidermal
growth factor (EGF) receptor sig-
naling (38, 40–43) remained unaf-
fected by treatment with siRNA tar-
geting CHC (Fig. 4A). We reasoned
that if LRR promoted clathrin-inde-
pendent Met endocytosis, then
receptor uptake would not be
altered in cells depleted of endogenous CHC. To test this idea
CHC-depleted cells were co-incubated with Alexa594-trans-
ferrin (Alexa-Tfn) and Alexa488-labeled InlB (Alexa-InlB) or
Alexa488-labeled LRR (Alexa-LRR) for 10 min at 37 °C using
ligand concentrations that induce comparable levels of Met
phosphorylation. Ligand uptake was measured using confocal
microscopy. CHC-siRNA abrogated Met endocytosis in
response to InlB and its derivative LRR but did not affect recep-
tor internalization in cells transfected with control siRNA.
Uptake of the fluid phase marker Alexa594-labeled dextran
10,000 was unaffected (supplemental Fig. S3), whereas Alexa-
Tfn internalization was reduced under these conditions (Fig.
4A). Collectively, these findings are consistent with a specific
block in clathrin-mediated endocytosis. Similarly, siRNA-me-
diated depletion of Grb2 blocked Met uptake in response to
LRR and InlB. The requirement for Grb2 was specific forMet
endocytosis, as clathrin-mediated uptake of Alexa-Tfn was
unaffected under these conditions (Fig. 4B). Thus, like InlB,
LRR triggers Met internalization through clathrin-coated
pits in a Grb2-dependent manner.
InternalizedMet Recycles in Response to LRR—Our data indi-
cate no difference in the internalization properties of Met in
FIGURE 4. Internalization of Met in response to LRR is clathrin- and Grb2-dependent. A, left panel, lysates
from untransfected HeLa cells (Un) or cells transfected with control (Con) or CHC siRNA were examined by
Western analysis using antibodies for CHC, transferrin receptor, Met, EEA1, and caveolin. Right panel, duplicate
sets of control or CHC-depleted HeLa cells were co-treated for 10 min at 37 °C with Alexa594-Tfn and Alexa488-
InlB, or Alexa488-LRR, and the relative amount of internalized ligand was analyzed by confocal microscopy.
Values represent themean fluorescence intensityS.E. from 2–3 experiments and are expressed as a percent-
age of control values. B, left panel, Western analysis was performed as indicated to confirm siRNA-mediated
depletion of Grb2 in HeLa cells. Right Panel, the relative amounts of internalized Tfn, InlB, and LRR in a 10-min/
37 °Cpulse inHeLa cells transfectedwith control (Con) or Grb2 siRNAswerequantifiedby confocalmicroscopy.
The average values of 2–3 experiments are expressed as a percentage of control values  S.E. (*, p  0.01,
ANOVA).
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response to InlB or LRR, suggesting that post-endocytic mech-
anisms contribute to the prolonged stability and signaling of
Met in response to LRR.After InlB-inducedMet internalization
into early endosomes, the receptor is normally sorted for deg-
radation in the lysosome (18). The delay inMet degradation we
observed after treatment with the LRR fragment could be the
result of a slower rate of transit through early endosomes
and/or enhanced receptor recycling to the cell surface. There-
fore, we used confocal microscopy to examine the distribution
of internalizedMet. Alexa-LRR and Alexa-InlB were employed
as indicators for receptor co-localization with endogenous
EEA1 and CD63, specific markers for early endosomes and
multivesicular bodies (MVB), respectively (44, 45). HeLa cells
were allowed to internalize Alexa-LRR or Alexa-InlB into early
endosomes at 37 °C for 15 min. After internalization, the cells
were washed and then chased at 37 °C for 0, 30, or 60 min in
media lacking ligand to promote Met trafficking from early
endosomes. The cells were then fixed and co-stained for endog-
enous EEA1 or CD63 and examined using confocal microscopy
(supplemental Fig. S4). Increased chase times resulted in
decreased Alexa-InlB co-localization with EEA1 with a con-
comitant increase in ligand co-staining with CD63, consistent
with Met trafficking from early endosomes to MVBs (Fig. 5A).
The lower levels of Alexa-InlB that co-localized with CD63 at
60 min (49%) may be the result of InlB-Met complex dissocia-
tion or lysosomal degradation under these chase conditions. In
contrast to Alexa-InlB-treated cells, high levels of Alexa-LRR
co-localized with EEA1 at the 30- and 60-min chase times (Fig.
5B). The decreased extent of Alexa-LRR co-localization with
CD63 at 30 min is consistent with a delay in Met trafficking
from early endosomes to MVBs.
To further examine the fate of InlB- versus LRR-activated
Met, we developed a flow cytometry assay to quantify the recov-
ery of internalized Met in the plasma membrane due to recep-
tor recycling. Cycloheximide-treated HeLa cells were incu-
bated inmedia lacking or containing ligand (2 nM InlB or 10 nM
LRR) for 15 min at 37 °C to promote Met internalization into
early endosomes. The cells were shifted to 4 °C to halt receptor
trafficking and then incubated with ice-cold 0.25% trypsin to
remove residual surface-associated receptor. After trypsin
inactivation, the cells were shifted to 37 °C in the presence of
cycloheximide for increasing times to promote receptor traf-
ficking. Flow cytometry was used to examine the reappearance
of internalized receptor on the cell surface using an antibody
specific for the ectodomain of Met. Under these conditions
receptor recyclingwas undetectable in cells treatedwith InlB or
untreated control cells (Fig. 6), consistent with a previous study
showing that InlB treatment results in the lysosomal degrada-
tion of Met (18). Conversely, increasing levels of surface Met
were readily detected in LRR-treated cells during the chase con-
ditions, consistent with the recycling of internalized Met back
to the plasma membrane. These results suggest that receptor
recycling to the cell surface is likely one of the causes of
increased Met stability in response to LRR.
Cell Motility Increases in Response to LRR—Our observation
that Met signaling in response to 10 nM LRR is sustained (refer
to Fig. 1B) suggested that LRR might promote cellular
responses resulting from Met signaling such as cell motility
and/or branchingmorphogenesis.MDCK cells are an epithelial
cell line that readily undergoes colony dispersal, increased cell
motility, and branching morphogenesis in response toMet sig-
naling (8, 46, 47). Thus, we tested the ability of MDCK cells to
form tubules in semisolid collagen in response to InlB or LRR.
As shown in supplemental Fig. S5, MDCK cells grown in three-
dimensional collagen gels form simple cystic structures in the
absence of ligand. Treatment of the control cysts with HGF for
7 days induced marked branching tubulogenesis into the sur-
rounding gel. Similarly, treatment for 7 days with InlB or LRR
resulted in the formation of long, thick tubules that were indis-
tinguishable from those induced by HGF.
We next examined MDCK cell motility in response to vari-
ousMet ligands. Serum-starvedMDCK cells were incubated in
media without ligand or containing HGF, InlB, wild type, or
mutant LRR for 8 h, and the scattering response was examined
using phase contrastmicroscopy. Under these conditions, HGF
and InlB were indistinguishable in their ability to induce cell
scattering. Conversely, LRR treatment stimulated MDCK scat-
tering in a dose-dependentmanner (Fig. 7A). No scattering was
FIGURE 5. Met transit from early endosomes to the MVB is delayed in
response to LRR.HeLa cellswere allowed to internalize Alexa488-labeled InlB
or LRR for 15min at 37 °C and then chased at 37 °C in the absenceof ligand for
increasing times to promote ligand transport from early endosomes to the
MVB. Cells were fixed and stained for endogenous EEA1 or CD63, and the
relative amount of internalized ligand that co-localizes with these proteins
was quantified using confocal microscopy. Values are expressed as the per-
centage of co-localization S.E. normalized to an area from three independ-
ent experiments (*, p 0.01, ANOVA).
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observed in the absence of ligand or after treatment with the
inactive LRR mutant C242A.
We quantified the effect of LRR and InlB onMDCKmotility
using scratch assays. In these studies cells were grown to con-
fluency and serum-starved for 48 h in media containing 0.1%
sera to ensure that cell migration rather than cell growth was
measured. Linear scratches were induced using a pipette tip,
and the width of the wound was measured in pixels. The cells
were then incubated in medium with 0.2% serum without or
with 2 nM InlB or 10 nM LRR for up to 6 h, at which time the
width of the denuded area was measured. As shown in Fig. 7, B
and C, cell motility increased in response to InlB and, to a
greater extent LRR, relative to control cells incubated in media
lacking ligand. The wound width was reduced to 45.99  1.7
and 28.56 1.5% that of the original size in response to InlB and
LRR respectively (Fig. 7). In control cells the wound decreased
to 92.7 2.25% that of its original width at 6 h. To confirm that
the increase in cell motility induced by LRR was not cell type-
specific, we performed scratch assays using HeLa cells. As
shown in supplemental Fig. S6,HeLa cellmotility in response to
LRR was higher than that induced by full-length InlB, consist-
ent with our motility studies using MDCK cells. Thus,
increased Met stability in response to LRR correlates with
increased motility of HeLa and MDCK cells.
DISCUSSION
Here we performed a structure/function analysis of the Lis-
teria protein InlB. A key finding from our studies is that InlB
and its N-terminal LRR fragment differentially regulate the
endocytic trafficking of Met. Notably, our results indicate that
in contrast to InlB, LRR attenuates Met degradation and pro-
longs Met phosphorylation, correlating with increased cell
motility. The effect of LRR on Met degradation is specific as
InlB and LRR induce comparable rates of clathrin-mediated
Met internalization. Moreover, Met recycles back to the cell
surface in response to LRR but not InlB. These results suggest
that alterations inMet degradation contribute at least in part to
differences in the potencies of InlB and LRR with respect to
receptor signaling.
How do InlB and LRR differ in their efficiency in inducing
Met degradation? One possible explanation is related to the
relative binding affinity of InlB versus LRR for Met. In the case
of the EGF receptor, EGF but not transforming growth factor-
induces efficient receptor degradation. EGF remains tightly
associated with the EGF receptor after receptor internalization,
whereas transforming growth factor- rapidly dissociates from
the receptor within the acidic environment of early endosomes,
resulting in receptor recycling to the cell surface (48). Our stud-
ies show a requirement for higher concentrations of LRR com-
pared with InlB to achieve comparable levels of Met autophos-
phorylation. These findings suggest that differences in the
binding affinities of InlB and LRR forMet likely exist. However,
LRR appears to remain associated with Met during transit
through early endosomes andMVBs. Like Alexa-InlB, internal-
ized Alexa-LRR is readily detected in EEA1- and CD63-positive
endocytic compartments. Althoughwe cannot exclude the pos-
sibility that ligand affinity for Met is altered during transit
through endocytic compartments, our studies support the con-
clusion that binding of LRRor InlB is not adversely disrupted by
early endosomal pH.
An alternative explanation involves the different quaternary
states of InlB and LRR. Receptor dimerization is the proposed
mechanism for Met activation, as bivalent antibodies directed
against the ectodomain of Met induce receptor phosphoryla-
tion and trigger several downstream biological responses,
including cell motility, proliferation, invasion, tubulogenesis,
and angiogenesis (49). InlB is a monomeric protein and could
activate Met through a mechanism similar to that observed
with EGF. EGF induces a conformational change in its receptor,
resulting in the unmasking of a cryptic dimerization motif in
the receptor extracellular domain (for review, see Refs. 50 and
51). In this way binding of EGF converts the EGF receptor from
a dimerization-inhibited state to a dimerization-competent
state. The key to this transition involves the initial formation of
an asymmetric EGF-EGF receptor dimer (52), in which one of
the EGF-bound monomers relieves autoinhibition from the
other receptor monomer resulting in an active conformation.
By analogy, InlB binding toMetmight induce a conformational
change that promotes receptor dimerization and, hence, recep-
tor activation. In contrast to InlB, LRR is a dimer in solution.
Therefore, LRRmay activateMet simply by clustering or cross-
linking two receptors. This would suggest that additional
regions absent from LRR (e.g. inter-repeat or GW domains)
could be required to induce a conformational change sufficient
for maximal Met activation.
A recentmodel described byNiemann et al. (14)may provide
an alternative explanation for the different agonist properties of
full-length InlB and its LRR fragment. Although InlB is a mon-
omer in solution, the authors propose that soluble InlB might
be clustered and form multimers upon interacting with hepa-
ran sulfate proteoglycans on the surface of host cells via theGW
domains of InlB. In this model InlB and LRR each act as mul-
timers capable of clustering Met. The structural data of
FIGURE 6. Internalized Met recycles in response to LRR. Cycloheximide-
treatedHeLa cellswere incubated inmedia lacking (Con) or containing ligand
(2 nM InlB or 10 nM LRR) for 15 min at 37 °C to internalize Met. The cells were
shifted to 4 °C, incubated in ice-cold trypsin to digest residual surface recep-
tor, and then shifted to37 °C in cycloheximide-containingmedia as indicated.
Recycled receptorwas labeledwith anti-Met antibody and quantified by flow
cytometry. Results represented the mean fluorescent intensities normalized
to control cells under each experimental condition from triplicate experi-
ments. Bars represent the means for data across all experiments with S.E. (*,
p 0.01, ANOVA).
Differential Met Degradation by InlB and Its Derivative LRR
JANUARY 9, 2009•VOLUME 284•NUMBER 2 JOURNAL OF BIOLOGICAL CHEMISTRY 781
Niemann et al. (14) suggests that the binding of InlB to Met
induces a change in theorientationof the semaand Ig1domains in
Met. The authors propose that the inter-repeat region in InlB is
needed for this re-orientation, which they refer to as “clamping.”
According to this model, the LRR fragment can bind and cluster
Met but cannot induce the structural change. Perhaps the inability
of the LRR fragment to clamp the receptor-ligand complex results
in an activated receptor with altered signaling activity compared
with the situation obtained with InlB binding.
Conformational changes induced by the binding of InlB ver-
sus LRR likely alter the ability of kinase-active Met to engage
components of the endocytic machinery and/or attenuate
downstream signalingmolecules important for receptor degra-
dation. Recent studies suggest a strong correlation between
Cbl-mediated Met ubiquitination and receptor down-regula-
tion. In addition to functioning as an adaptor protein for Met
(53), Cbl also serves as an E3 ubiquitin ligase (54–57) to ubiq-
uitinate target proteins includingMet (56, 57). AlthoughCbl E3
ubiquitin ligase activity regulates Met endocytosis, Cbl-medi-
ated Met ubiquitination is not required for receptor internal-
ization per se but is needed for effi-
cient receptor down-regulation (19,
28). Consistent with these findings, a
somatic intronic mutation identified
in lung cancer results in aMet recep-
tor mutant that shows decreased Cbl
binding, increased Met stability, and
tumorigenesis (58). Similarly, an arti-
ficial mutation introduced into the
juxtamembrane region of Met
(Y1003F) which inhibits recruit-
ment of Cbl increases Met stability
and promotes cell proliferation in
response toHGF (28). However, it is
unclear from these studies whether
the respective Met mutants recycle
to the cell surface or remain on
intracellular membranes. In our
hands internalized Met does not
normally recycle back to the cell
surface in response to HGF.3
Although the mechanistic basis of
LRR- versus InlB-induced changes
in Met trafficking remain unclear, it
is tempting to speculate that Cbl
activation and binding or Cbl-medi-
ated ubiquitination of Met may be
attenuated in LRR-treated cells,
leading to receptor recycling and,
hence, increasedMetstabilityandsig-
naling. Consistent with this scenario,
LRR treatment promotes motility of
MDCK andHeLa. Because lysosomal
sorting is a saturable process (59),
additional factors downstream of Cbl
may alsobe rate-limiting forMetdeg-
radation in LRR-treated cells.
In conclusion, we report the first
evidence that Met alters its trafficking pattern in response to a
truncated derivative of InlB, the LRR fragment. Altered Met
trafficking results in increased receptor stability and recycling
to the cell surface, correlating with prolonged Met signaling
and cell motility. These studies support the contention that
alterations in Met endocytic trafficking can augment receptor
signaling and, hence, cellular responses. Additional studies will
be required to determine how InlB and its fragment LRR alter
the ability of kinase-active Met to interact with critical compo-
nents of the endocytic machinery important for receptor sort-
ing and degradation.
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